Elizabeth Glaser Pediatric AIDS Foundation

Partnership Objective

The partnership seeks to prevent pediatric HIV infection and to eradicate pediatric AIDS through research, advocacy, and prevention and treatment programs.

Adult access to treatment for HIV/AIDS outpaces that of children almost two to one. Adult access to treatment for HIV/AIDS outpaces that of children almost two to one. Copyright ViiV Healthcare

Description of partnership activities and how they address needs and challenges

The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is an internationally recognized leader in the fight against pediatric AIDS. Since its inception in 1998 as a U.S.– based non-profit 501(c)(3), EGPAF has been at the global forefront of the fight to prevent pediatric HIV infection and to eliminate pediatric AIDS through research, advocacy, and prevention, care, and treatment programs. EGPAF works in 15 countries around the world and collaborates with host governments, health facilities, non-governmental organizations and community-based organizations to halt the pandemic and help those already infected with HIV to lead healthier lives. 

EGPAF provides a full range of critical HIV services by increasing access to prevention of mother-to-child transmission (PMTCT) services, and care and treatment for children and families, linking services, and training leaders in advancing quality care. EGPAF places great emphasis on capacity building and technical assistance. It assists international government partners to strengthen their country’s health systems and provide training to help ensure the effective sustainability of their prevention, care, and treatment programs.

EGPAF has reached 20 million women with lifesaving services to prevent transmission of HIV to their babies. As of December 2013, EGPAF has tested nearly 16.6 million women for HIV. More than 1.32 million pregnant women and 893,000 children have been provided with  antiretroviral (ARV) prophylaxis through EGPAF services.

EGPAF's comprehensive approach includes prevention, diagnosis, and treatment of opportunistic infections such as pneumonia and tuberculosis. EGPAF is working to increase identification and care and treatment of young HIV-positive or HIV-exposed children and their mothers, through maternal, neonatal and child health (MNCH) clinics, general clinics, and inpatient wards. EGPAF is also implementing routine testing of children and/or mothers of unknown HIV status in well-child clinics and inpatient pediatric wards.


Until No Child Has AIDS

Partnership information

Company(ies) Johnson & Johnson

Partner(s) Bill and Melinda Gates Foundation, Canadian International Development Agency (CIDA), Center for Disease Control and Prevention (CDC), Dimagi, Elizabeth Glaser Pediatric AIDS Foundation, FHI Development 360, John Snow Inc, PATH, UK Department for International Development (DFID), UNICEF, United Airlines, US Agency for International Development (USAID), US Peace Corps, ViiV Healthcare, World Health Organization (WHO), World Vision

Type of Partner(s) Government, IGOs, NGOs, Other Business

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Program Type(s) Availability of Treatment - Product Donations, Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach

Targeted Population(s) Children, Mothers, Patients in needs of treatment, Women, Youth

Region(s) South Asia, Sub-Saharan Africa

Number of Countries 14

Country(ies) Cameroon, Côte d'Ivoire, Democratic Republic of the Congo, India, Kenya, Lesotho, Malawi, Mozambique, Rwanda, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe

Start Date 1988

More information EGPAF

Anticipated completion date Ongoing